Endpoints:Alzheimer’s drug bites the dust
Roche is stopping all studies with its anti-amyloid drug gantenerumab in early Alzheimer’s disease after the drug, which had disappointed in late-stage trials years ago, failed two Phase III trials in the highly anticipated GRADUATE program. Notably, not only did it miss the primary endpoints of slowing clinical decline, the level of beta-amyloid removal was also lower than expected — giving proponents of the amyloid hypothesis a talking point as Biogen and Eisai establish a lead with lecanemab.
Endpoints:Alzheimer’s drug bites the dustRoche is stopping all...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $119.6M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $46.86K | 4.283M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 25268416 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 18128695 | 9 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| ATH (ASX) Chart |